

T-Bird Pharma Inc. Appoints Sandy Pratt as Chief Financial Officer

Victoria, British Columbia, January 27, 2015 – T-Bird Pharma Inc. (TSXV:TPI) (“T-Bird” or the “Company”), a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer (“LP”) under the *Marihuana for Medical Purposes Regulations (Canada)* (“MMPR”), wishes to announce that Sandra (Sandy) Pratt has joined the Company as Chief Financial Officer, replacing Chris Taylor who has stepped down to return to his private practice. Taylor will remain involved with the Company at the Board level by continuing on as Corporate Secretary and operationally as an RPIC and consultant. “Chris’ background in our history and operations is valuable so we are very pleased to see that he has agreed to remain involved with the Company at the Board level” noted David Raffa, Chairman of the Board. Added Raffa, “the addition of Sandy to our team represents another step in increasing the operational experience within our company as we commercialize our operation. We are very pleased she has agreed to join our team.”

Ms. Pratt is a CPA/CA who began her career in public practice with Deloitte where she had a large number of public and private company clients. Ms. Pratt left private practice to join Angiotech in its early stages and experienced the challenges and excitement of being a core member of a high growth pharma company. During her tenure with Angiotech, first as controller and then as Director of Finance, the company grew from an organization of two to 45 companies, and from pre-revenue to over \$300 million in revenues. Ms. Pratt was a key part of the finance and M&A teams.

More recently, Ms. Pratt served as Vice-President of Finance at the Oak Bay Marine Group where her duties covered all aspects of financial operations. In addition to her finance role, she also led sales and marketing and was co-responsible for all aspects of the conglomerate’s operations together with one other senior officer. “It is Sandy’s broad operational experience that attracted us to her,” noted Dr. Bin Huang, CEO of the Company. “Sandy’s skill set goes beyond that of a typical CFO having been involved at various points in her career with operations, business development, sales and marketing and human resources.”

Ms. Pratt has been granted an option to acquire up to 350,000 common shares vesting over three years.

About T-Bird and Thunderbird

T-Bird Pharma Inc. is the parent company of Thunderbird Biomedical Inc., a wholly owned private subsidiary formed in January, 2013. The principal activities of Thunderbird are the production of marijuana from its Victoria, British Columbia production facility, as regulated by the *Marihuana for Medical Purposes Regulations (Canada)*. Thunderbird

obtained a medical marijuana license to undertake the production of medical marijuana in February 2014, being the fifth company in Canada to obtain such a license. Thunderbird was acquired by T-Bird in September, 2013.

ON BEHALF OF THE BOARD

“David Raffa”

Chairman

For further information, please contact: Kam Thindal at 604-488-9875.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.

We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including production and sales of medical marijuana, anticipated revenues, projected size of market, quantities of future medical marijuana production, completion of production facilities and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

T-Bird Pharma Inc. (the “**Company**”) does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, results of production and sale activities, the Company’s historical experience with medical marijuana operations, uninsured risks, regulatory changes, availability of production facilities, timeliness of government approvals and the granting of permits and licenses, changes in prices, actual operating and financial performance of facilities, equipment and processes relative to specifications and expectations. Actual results may differ materially from those expressed or implied by such forward-looking statements.